Business Context and Reporting Period
This Form 8-K was filed by Bristol-Myers Squibb Company on March 26, 2019, reporting events occurring on March 25, 2019. The filing addresses the ongoing merger agreement between Bristol-Myers Squibb and Celgene Corporation, specifically regarding regulatory review status.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes and Events
- FTC Second Request: On March 25, 2019, both Bristol-Myers Squibb and Celgene received a "Second Request" for additional information and documentary materials from the U.S. Federal Trade Commission (FTC).
- Regulatory Focus: The FTC's review is focused on marketed and pipeline products for the treatment of psoriasis.
- Waiting Period Extension: The Second Request extends the Hart-Scott-Rodino (HSR) Act waiting period until 30 days after the parties substantially comply with the request, unless extended voluntarily or terminated sooner by the FTC.
Guidance, Outlook, and Risks
- Transaction Timing: Management states that the previously communicated transaction timing is not affected by the Second Request. Both parties continue to expect the merger to be consummated in the third quarter of 2019.
- Conditions to Closing: Completion remains subject to the expiration or termination of the HSR waiting period and the satisfaction or waiver of other closing conditions.
- Risk Factors: The filing includes extensive forward-looking statements cautioning that actual results may differ due to regulatory delays, failure to obtain approvals, inability to achieve synergies, integration challenges, and market conditions. It explicitly notes that projected financial information has not been prepared in conformance with Regulation S-X.
Investor Verification Checklist
- Verify the status of the FTC "Second Request" compliance and any subsequent extensions to the HSR waiting period.
- Review the definitive joint proxy statement/prospectus filed on Form S-4 for detailed terms of the merger and participant interests.
- Monitor for updates regarding the FTC's investigation into psoriasis treatment products.
- Confirm the continued expectation of a third-quarter 2019 closing date in future filings.